A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. - Wikidata - wikimedia - TriplyDB

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

http://www.wikidata.org/entity/Q33345998

about

Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes Guidelines for the management of myeloproliferative neoplasms Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors Advances in the management of myelofibrosis The evolving treatment paradigm in myelofibrosis Practical management of classical myeloproliferative disorder patients: a clinician's guide Thalidomide for the treatment of idiopathic myelofibrosis.Modern management of myelofibrosis.Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.A phase-2 trial of low-dose pomalidomide in myelofibrosis.Immunomodulatory agents in myelofibrosis.Emerging drugs for myelofibrosis.Ruxolitinib: a new treatment option for myelofibrosis.Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.Thalidomide treatment in a myelofibrosis patient with leukemia transformation.Long-term results of prednisone treatment for the anemia of myelofibrosis.Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.Alleviating anemia and thrombocytopenia in myelofibrosis patients.Safety considerations when treating myelofibrosis.Managing patients with myelofibrosis and low platelet counts.Outcome of transplantation for myelofibrosis.Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Modest activity of pomalidomide in patients with myelofibrosis and significant anemia Choosing between stem cell therapy and drugs in myelofibrosis.Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Rα.Profile of pomalidomide and its potential in the treatment of myelofibrosis.The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.Thalidomide for the treatment of multiple myeloma.Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.Thalidomide and immunomodulatory drugs in the treatment of cancer.Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis.Ruxolitinib for myelofibrosis.Allogeneic stem cell transplantation as treatment for myelofibrosis.The evolving role of lenalidomide in the treatment of hematologic malignancies.

P2860

Q26752940-05595ADF-E59D-4C2A-BABA-3B03A07DBBFA Q26778326-B10475D8-7EAE-4A31-9918-83F1DAF0126A Q26863610-650ED28B-1F1D-4D0F-81AF-828C60C6DA60 Q27008072-B6313502-B8FD-4DA9-9C0B-A6568572C378 Q27021968-860CE6BC-4168-44AD-8D8A-D90012FC03E9 Q28200207-01439E03-491B-4BFC-9BD2-A613B9CB375F Q33359542-B54A3F0C-A61A-4983-A5C7-4615E8257413 Q33365122-6D2900E1-ACF5-4F74-B5BB-2D2152C5DF83 Q33386057-2BF35E05-16E9-4955-8F77-EC5A9D909337 Q33392689-458791E3-44F4-4474-A537-7E47FEC30C81 Q33401615-13085567-1D3F-4B52-AF29-B903BCD7B1E0 Q33404574-9481FAA8-D015-446B-AD42-73F928F5E6E0 Q33405241-3E5865F7-9B17-4F5C-88EE-1C49232ECAE2 Q33406035-10BC69C5-FED9-4728-BDDC-2327FF3F747C Q33411894-820F7271-FA8E-4E34-8CC0-8A645D3F1115 Q33422565-60B24A35-3837-405E-AF3E-10BAF6318A2D Q33423956-5C5C05C1-6D79-4DE6-91D3-0B8958CC8C7B Q33430113-3F3B76E4-0AC0-4587-BD7C-49C419A9B57E Q33432285-F9788B28-4743-4DFC-BF55-CD68BFC2CAF2 Q33432406-180D7E6F-77D3-4337-AD43-15744432DE9B Q34015474-46DD3F9E-3086-4F33-A4AE-1B2A22BC80F2 Q34146512-86420A25-2211-43F1-9E16-924ACCDF923E Q34150008-2936E43A-FBC3-48F9-BBE9-FB12B5C6FF0B Q34162867-CBF76136-9D2D-4DE9-8358-FC977FE1F9B6 Q34165935-102CBDA1-FB51-4BFC-BFF6-EA4E0FC7BBFB Q34253548-374CB751-C24E-4C58-89E1-2EFB1C8C72D6 Q34302770-687A61C8-89E0-4BFA-983B-51B7603E8DC9 Q34512203-B91EC15D-2B24-4719-A3C1-29D26F2CE90B Q34734491-24CE8AA5-4E7B-4E8C-B1F7-68CBD6A48243 Q35203067-80502F79-7161-41BC-8521-28C366415D19 Q35427915-D002C014-4F78-4450-8EAF-65F1C96FA9E3 Q35849342-7AEA6307-7656-4D62-8D5A-2FA7CD1E75A4 Q35870500-9E101DFE-DD95-4450-8A55-F1C5E4C5452C Q35937081-FDFE790E-36DE-4D50-9EC7-EFBFD1547B92 Q36001930-199652EE-8EAC-46ED-AF77-E4C4BDE0F779 Q36040871-257CC089-BACC-4D52-B064-B6B3A8AF43AE Q36047069-43682259-E60E-45E0-95A2-CE0397BEC8B5 Q36604028-9285C731-F076-486D-9B99-4C6C81A8EFF7 Q36609417-7AED285A-E29B-40B9-B115-B0567F9326C6 Q36739807-748788E8-D51C-40B9-8202-F430B78D031C

P2860

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

http://www.wikidata.org/entity/Q33345998

description

2002 nî lūn-bûn

@nan

2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

A phase 2 trial of combination ...... rosis with myeloid metaplasia.

@ast

A phase 2 trial of combination ...... rosis with myeloid metaplasia.

@en

type

label

A phase 2 trial of combination ...... rosis with myeloid metaplasia.

@ast

A phase 2 trial of combination ...... rosis with myeloid metaplasia.

@en

prefLabel

A phase 2 trial of combination ...... rosis with myeloid metaplasia.

@ast

A phase 2 trial of combination ...... rosis with myeloid metaplasia.

@en

P1433

Q33345998-C75ED154-0276-43D0-9244-077B20EA77E7

P1476

Q33345998-F77BAB62-E798-4DAE-8FED-8B8F6839000D

P2093

Q33345998-17141753-FBA8-4428-A620-98A2729A3611

Q33345998-22F27CC5-A30E-41DA-8022-D6259A8F258B

Q33345998-3FD1CA04-B519-4674-B7E6-2839363D1066

Q33345998-445365CF-51B4-4A75-9EF3-D00B01396B00

Q33345998-58860AB6-8E4B-465E-BFC6-80FC688E306B

Q33345998-5B6F7A5D-BFFC-4E58-B65D-4B54609E3395

Q33345998-62BAEF33-F419-4C50-846C-DA6905D436A1

Q33345998-7516F671-05E4-4785-B308-B2A7AB1DF50A

Q33345998-A618D0D4-1FDB-4E14-A8DC-0B910B5641EE

Q33345998-BD07C1F2-5C84-41FC-9390-7D86D7E9FAA4

P304

Q33345998-C2DBD3B6-A073-4438-9D35-181630E42E74

P31

Q33345998-0700DA2E-00DB-4BF8-915B-DB84AA44CDEC

P356

Q33345998-DB8C97C2-D619-4ED5-92EA-0467749FA5E0

P407

Q33345998-A4306C21-AC76-42FE-BF9D-24AF4BD771CF

P433

Q33345998-D8207958-884A-4D6B-A3A0-95E1DD8026E5

P478

Q33345998-AB854343-0242-4EAF-9F26-DACB4C895C15

P50

Q33345998-9389E36E-AEDB-4C0A-9F08-64142867CE15

Q33345998-E0AF6976-39D5-4F57-98EC-53CE2A4420E8

P577

Q33345998-CA7A5DD8-E0D6-4460-93B7-5646F7635C08

P5875

Q33345998-A049EECD-F39D-422B-8FBB-A70DEAA79A62

P698

Q33345998-6C2692F4-5669-4992-8ADF-4DE39A814CE6

P921

Q33345998-CAAE2ECF-9EF7-4764-8321-E68146543A4D

Q33345998-D7A01E25-72B3-46F9-A558-10122EFBDB79

P356

BLOOD-2002-09-2928

P1433

P1476

A phase 2 trial of combination ...... rosis with myeloid metaplasia.

@en

P2093

Animesh Pardanani

http://www.w3.org/2001/XMLSchema#string

Chin-Yang Li

http://www.w3.org/2001/XMLSchema#string

Georgene Schroeder

http://www.w3.org/2001/XMLSchema#string

Gregory Wiseman

http://www.w3.org/2001/XMLSchema#string

Jerome B Zeldis

http://www.w3.org/2001/XMLSchema#string

Leigh A Gray

http://www.w3.org/2001/XMLSchema#string

Michelle Elliott

http://www.w3.org/2001/XMLSchema#string

Ruben A Mesa

http://www.w3.org/2001/XMLSchema#string

Scott H Kaufmann

http://www.w3.org/2001/XMLSchema#string

Terra Reeder

http://www.w3.org/2001/XMLSchema#string

P304

2534-2541

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2002-09-2928

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

David P. Steensma

P577

2002-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10959215

http://www.w3.org/2001/XMLSchema#string

P698

12517815

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial